Neurological Complications after COVID-19 Vaccination

被引：0
作者：
Khalimova K.M. [1 ]
Rashidova N.S. [1 ]
Salimjonov J.J. [1 ]
机构：
[1] Tashkent Medical Academy, Tashkent
来源：
Neuroscience and Behavioral Physiology | 2024年 / 54卷 / 4期
关键词：
complications; COVID-19; vaccination;
D O I：
10.1007/s11055-024-01624-8
中图分类号：
学科分类号：
摘要：
The aim of the present work was to study the relevance and incidence of the development of neurological post-vaccination complications during the COVID-19 pandemic. Diagnosed complications, including neurological complications, occurring after administration of the COVID-19 vaccine during the pandemic are described on the basis of the results of a systematic literature search of several databases. Continued long-term studies are needed to fully establish the pathophysiological mechanisms of the causal relationship between neurological complications and COVID-19 vaccines. This will allow pharmacological correction of vaccine safety profiles. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.
引用
收藏
页码：540 / 546
页数：6
相关论文
共 86 条
[1]  
Director-General’s Opening Remarks at the Media Briefing on COVID-19, (2020)
[2]  
Anderson E.J., Rouphael N.G., Widge A.T., Et al., Safety and immunogenicity of SARSCoV-2 mRNA-1273 vaccine in older adults, N. Engl. J. Med, 383, pp. 2427-2438, (2020)
[3]  
Jackson L.A., Anderson E.J., Rouphael N.G., Et al., An mRNA vaccine against SARS-CoV-2. Preliminary report, N. Engl. J. Med, 383, pp. 1920-1931, (2020)
[4]  
Sadoff J., Gray G., Vandebosch A., Et al., Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19, N. Engl. J. Med, 384, pp. 2187-2201, (2021)
[5]  
Walsh E.E., Frenck R.W., Falsey A.R., Et al., Safety and immunogenicity of two RNA-based COVID-9 vaccine candidates, N. Engl. J. Med, 383, 2450, pp. 2439-5240, (2020)
[6]  
Dai L., Gao L., Tao L., Et al., Efficacy and safety of the RBDdimer-based Covid-19 vaccine ZF2001 in adults, N. Engl. J. Med, 386, pp. 2097-2111, (2022)
[7]  
Commission Implementing Decision of 21.12.2020 Granting a Conditional Marketing Authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for “Comirnaty – COVID-19 Mrna Vaccine (Nucleoside Modified),” a Medicinal Product for Human Use, (2020)
[8]  
Commission E., Commission Implementing Decision of 6.1.2021 Granting a Conditional Marketing Authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for “COVID-19 Vaccine Moderna – COVID-19 Mrna Vaccine (Nucleoside Modified),” a Medicinal Product for Human Use, European Commission, Brussels, (2021)
[9]  
US Department of Health and Human Services, (2020)
[10]  
(2020)
123456789